NASDAQ · Health care

Polaryx Therapeutics, Inc. (PLYX)

It posted a net loss of $9M. At June 30, 2026 it held $11.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.

What Polaryx Therapeutics, Inc. does

Polaryx Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker PLYX.

Revenue and profit by year

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	n/a	-$7.8M	-$9M	-$0.20	n/a
2025	n/a	-$4.4M	-$30.4M	-$0.89	n/a

Latest SEC filings

What Polaryx Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

September 14, 2026
Shareholder vote results 8-K
September 1, 2026
Investor disclosure 8-K
August 13, 2026
Quarterly report 10-Q · period to June 30, 2026
July 28, 2026
Annual report to shareholders ARS
July 28, 2026
Additional proxy material DEFA14A
July 28, 2026
Proxy statement DEF 14A
July 24, 2026
Employee stock plan registration S-8
July 21, 2026
Executive or director change 8-K
July 17, 2026
Shareholder nomination deadline 8-K
May 28, 2026
Material agreement 8-K

Recent insider filings (Forms 3, 4 and 144): 9, the latest on May 28, 2026. Insider transactions on SEC

All filings on SEC EDGAR

Questions about PLYX

What does Polaryx Therapeutics, Inc. do?

Polaryx Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker PLYX.

Is Polaryx Therapeutics, Inc. profitable?

No. In fiscal 2025 it reported a net loss of $9M.

When did Polaryx Therapeutics, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the shareholder vote results from September 14, 2026.

Similar companies

Follow PLYX

Get an email when Polaryx Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow PLYX: get an email when it files

Where the numbers come from

Financial figures are the values Polaryx Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.